RxDoctor Payments Data

Randal White, MD

Cardiovascular Disease · San Antonio, TXNPI 1851378889

Payments from drug & device makers

$59,116in general payments, 2019–2025

Across 465 payments — averaging $127.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$35K
  • Amarin Pharma, Inc.$11K
  • Alnylam Pharmaceuticals Inc.$7K
  • Novartis$1K
  • Merck$537
  • Esperion Therapeutics, Inc.$524
  • plus $4K from 29 others

What the payments were for

  • Consulting fees$5,1009%
  • Speaking & faculty fees$42,23371%
  • Travel & lodging$2,6014%
  • Food & beverage$9,14415%
  • Education$380%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$59,116 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$189,702
Medicare patients
1,166
Services billed
2,991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban207$239,763
Repatha SureclickEvolocumab140$137,292
EntrestoSacubitril/Valsartan90$99,683
XareltoRivaroxaban24$36,551
Praluent PenAlirocumab25$30,700
FarxigaDapagliflozin Propanediol18$25,011
NexletolBempedoic Acid29$22,870
Icosapent Ethyl65$16,286
NexlizetBempedoic Acid/Ezetimibe39$15,828
VascepaIcosapent Ethyl29$12,914
Ezetimibe447$11,093
Atorvastatin Calcium486$6,210
Rosuvastatin Calcium306$5,417
Telmisartan162$4,470
Metoprolol Succinate232$3,965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35,111$239,763207 claims
NovartisEntresto$1,153$99,68390 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$524$38,69968 claims
Johnson & JohnsonXarelto$480$36,55124 claims
AstraZenecaFarxiga$160$25,01118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →